Efficacy of typhoid conjugate vaccine: final analysis of a 4-year, phase 3, randomised controlled trial in Malawian children.

Autor:	Patel PD; Malawi-Liverpool-Wellcome Program, Kamuzu University of Health Sciences, Blantyre, Malawi., Liang Y; Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, USA., Meiring JE; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK., Chasweka N; Malawi-Liverpool-Wellcome Program, Kamuzu University of Health Sciences, Blantyre, Malawi., Patel P; Malawi-Liverpool-Wellcome Program, Kamuzu University of Health Sciences, Blantyre, Malawi., Misiri T; Malawi-Liverpool-Wellcome Program, Kamuzu University of Health Sciences, Blantyre, Malawi., Mwakiseghile F; Malawi-Liverpool-Wellcome Program, Kamuzu University of Health Sciences, Blantyre, Malawi., Wachepa R; Malawi-Liverpool-Wellcome Program, Kamuzu University of Health Sciences, Blantyre, Malawi., Banda HC; Malawi-Liverpool-Wellcome Program, Kamuzu University of Health Sciences, Blantyre, Malawi., Shumba F; Malawi-Liverpool-Wellcome Program, Kamuzu University of Health Sciences, Blantyre, Malawi., Kawalazira G; District Health Office, Blantyre District Council, Blantyre, Malawi., Dube Q; Ministry of Health, Blantyre, Malawi., Nampota-Nkomba N; Blantyre Malaria Project, Kamuzu University of Health Sciences, Blantyre, Malawi., Nyirenda OM; Blantyre Malaria Project, Kamuzu University of Health Sciences, Blantyre, Malawi., Girmay T; Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, USA., Datta S; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA., Jamka LP; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA., Tracy JK; Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, USA., Laurens MB; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA., Heyderman RS; Division of Infection and Immunity, University College London, London, UK., Neuzil KM; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address: kneuzil@som.umaryland.edu., Gordon MA; Malawi-Liverpool-Wellcome Program, Kamuzu University of Health Sciences, Blantyre, Malawi.
Jazyk:	angličtina
Zdroj:	Lancet (London, England) [Lancet] 2024 Feb 03; Vol. 403 (10425), pp. 459-468. Date of Electronic Publication: 2024 Jan 25.
DOI:	10.1016/S0140-6736(23)02031-7
Abstrakt:	Background: Randomised controlled trials of typhoid conjugate vaccines among children in Africa and Asia have shown high short-term efficacy. Data on the durability of protection beyond 2 years are sparse. We present the final analysis of a randomised controlled trial in Malawi, encompassing more than 4 years of follow-up, with the aim of investigating vaccine efficacy over time and by age group. Methods: In this phase 3, double-blind, randomised controlled efficacy trial in Blantyre, Malawi, healthy children aged 9 months to 12 years were randomly assigned (1:1) by an unmasked statistician to receive a single dose of Vi polysaccharide conjugated to tetanus toxoid vaccine (Vi-TT) or meningococcal capsular group A conjugate (MenA) vaccine. Children had to have no previous history of typhoid vaccination and reside in the study areas for inclusion and were recruited from government schools and health centres. Participants, their parents or guardians, and the study team were masked to vaccine allocation. Nurses administering vaccines were unmasked. We did surveillance for febrile illness from vaccination until follow-up completion. The primary outcome was first occurrence of blood culture-confirmed typhoid fever. Eligible children who were randomly assigned and vaccinated were included in the intention-to-treat analyses. This trial is registered at ClinicalTrials.gov, NCT03299426. Findings: Between Feb 21, 2018, and Sept 27, 2018, 28 130 children were vaccinated; 14 069 were assigned to receive Vi-TT and 14 061 to receive MenA. After a median follow-up of 4·3 years (IQR 4·2-4·5), 24 (39·7 cases per 100 000 person-years) children in the Vi-TT group and 110 (182·7 cases per 100 000 person-years) children in the MenA group were diagnosed with a first episode of blood culture-confirmed typhoid fever. In the intention-to-treat population, efficacy of Vi-TT was 78·3% (95% CI 66·3-86·1), and 163 (129-222) children needed to be vaccinated to prevent one case. Efficacies by age group were 70·6% (6·4-93·0) for children aged 9 months to 2 years; 79·6% (45·8-93·9) for children aged 2-4 years; and 79·3% (63·5-89·0) for children aged 5-12 years. Interpretation: A single dose of Vi-TT is durably efficacious for at least 4 years among children aged 9 months to 12 years and shows efficacy in all age groups, including children younger than 2 years. These results support current WHO recommendations in typhoid-endemic areas for mass campaigns among children aged 9 months to 15 years, followed by routine introduction in the first 2 years of life. Funding: Bill & Melinda Gates Foundation. Competing Interests: Declaration of interests YL, SD, LPJ, MBL, and KMN receive funding from the TyVAC grant (grant number OPP1151153). KMN is a voting member of the WHO Strategic Advisory Group of Experts on Immunization (SAGE). RSH is a UK National Institute for Health and Care Research Senior Investigator. All other authors declare no competing interests. (Copyright © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu